Skip To Main Content
Philipp Berning on Muck Rack

Philipp Berning

As seen in: Nature, Cell Press, Journal of Interventional Radiology (JVIR)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Philipp Berning’s profile

Articles by Philipp Berning

Pre–CAR-T B-cell–directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis

|
By Jan Schroeder, Christophe Peczynski, Philipp Berning, Eva Michel, Lucas Mix, Andreas Riedel, Robin Sanderson, Urban Novak, Ron Ram, David Beauvais, Daniela Taurino, Robin Noel, Lucía López Corral, Almudena Cabero, Ralph Wäsch, Malte von Bonin, Peter Vandenberghe, Olaf Penack, Björn Chapuy, Avichai Shimoni, Barbara Dreta, Ulf Schnetzke, Eugenio Galli, Tobias Holderried, Claudia Lengerke, Norbert Schmitz, Wolfgang Andreas Bethge, Fizza Imran, Maria-Luisa Schubert, Maxime Delforge
| Nature Verified
CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) is standard-of-care second-line treatment for relapsed or refractory large B-cell lymphoma (LBCL) [1,2,3]. Bispecific antibodies (BSA) and polatuzumab vedotin (pola) are increasingly used prior to CAR-T, but the impact of such exposure, particularly before leukapheresis, when therapies may affect T-cell collection and fitness, remains unclear [4,5,6,7].
Open in Who Shared Issue with article?

Pathogenesis of diffuse large B cell lymphoma proteogenotypes

|
By Julius C. Enssle, Björn Häupl, Arber Qoku, Boya Wang, George Wright Verified, Sharon Barrans, Yulai Zhou, Matthew A. Care, Cathy Burton, Caitlin Gribbin, Jennifer Ziello, Jason L. Weirather, Yibo Dai, Atish Kizhakeyil, Xubin Li, James Phelan, Smriti Kanangat, Stephan Eckert, Sebastian Scheich, Da Wei Huang, Josefine Jakob, Sebastian P. Perner, Andrea Di Fonzo, Martine Pape, Marion Bodach, Dominique Jahn, Uwe Plessmann, Annette M. Staiger, German Ott, Philipp Berning, Georg Lenz, Daniel Hodson, Bernhard Kuster, Roland Schmitz, Henning Urlaub, Michael Green, Ari M Melnick, Reuben M. Tooze, Coraline Mlynarczyk, Giorgio G. Inghirami, Florian Buettner, Louis M. Staudt, Thomas Oellerich
| Cell Press Verified
Keywords lymphoma genomics proteomics tumor microenvironment immune exhaustion multi-omics data integration MYC B cell receptor single cell sequencing protein translation Introduction Diffuse large B cell lymphoma (DLBCL) is a genetically and clinically heterogeneous disease. While about 60–70% of patients with DLCBL can be cured with R-CHOP chemoimmunotherapy, 30–40% relapse or are refractory to treatment.
Open in Who Shared Issue with article?

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis

|
By Philipp Berning, Markus Maulhardt, Snjezana Janjetovic, Anna Ossami Saidy, Christian Schultze-Florey, Simon Call, Friedrich Stölzel, Annamaria Brioli, Michael Daskalakis, Rebecca I. Wurm-Kuczera, Matthias Stelljes, Cyrus Khandanpour, Ulrike Bacher, Amelie Boquoi, Florian H. Heidel, Hans Reinhardt, Gerald G. Wulf, Natalie Schub, Bastian von Tresckow, Georg Lenz, Thomas Pabst, Evgenii Shumilov, Hristo Boyadzhiev, Anca-Maria Albici, Juliane Knust, Justin Hasenkamp, Alexander Pohlmann
| Nature Verified
Dear Editor, The introduction of chimeric antigen receptor T-cell (CAR-T) therapies has significantly transformed the treatment landscape for patients with relapsed/refractory (r/r) multiple myeloma (MM). BCMA-directed CAR-T cell therapies, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), have revolutionized the field by demonstrating remarkable efficacy in pivotal clinical trials [1, 2].
Open in Who Shared Issue with article?

Immune reconstitution in AML and MDS patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with treosulfan- or TBI-based conditioning | Bone Marrow Transplantation

|
By Lina Kolloch, Philipp Berning, Jörn C. Albring, Julian Ronnacker, Christoph Schliemann, Georg Lenz
| Nature Verified
To the Editor: Cellular and humoral immune reconstitution after allo-HCT impacts infections, graft-versus-host disease (GvHD) and relapse-risk. How conditioning regimens affect immune recovery is largely unknown. A study comparing fludarabine/treosulfan (FluTreo) and fludarabine/total body irradiation (FluTBI) conditioning regimens showed no significant differences in overall survival (OS) and relapse-free survival (RFS) or GvHD incidence [1].
Open in Who Shared Issue with article?

Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years | Blood Cancer Journal

|
By Philipp Berning, Peter Dreger, Silvia Montoto, Edouard Forcade, Marek Trneny, Catherine Thieblemont, Anna Sureda
| Nature Verified
Abstract Autologous(auto-) and allogeneic(allo-) hematopoietic stem cell transplantation (HSCT) are key treatments for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), although their roles are challenged by CAR-T-cells and other immunotherapies. We examined the transplantation trends and outcomes for DLBCL patients undergoing auto-/allo-HSCT between 1990 and 2021 reported to EBMT.
Open in Who Shared Issue with article?

Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients | Bone Marrow Transplantation

|
By Philipp Berning, Jörn C. Albring, Christoph Schliemann, Georg Lenz
| Nature Verified
Abstract Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a standard treatment for patients with AML and MDS. The combination of fractionated total body irradiation(8GyTBI/Flu) with fludarabine is an established conditioning regimen, but fludarabine/treosulfan(Flu/Treo) constitutes an alternative in older/comorbid patients.
Open in Who Shared Issue with article?

Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis - Leukemia

|
By Philipp Berning, Norbert Schmitz, Arnaud Jaccard, Daihong Liu, Yves Chalandon, Eva Wagner-Drouet, Xi Zhang, Ibrahim Yakoub-Agha, Peter Dreger
| Nature Verified
Abstract Natural killer/T-cell lymphomas (NKTCL) represent rare and aggressive lymphoid malignancies. Patients (pts) with relapsed/refractory disease after Asparaginase (ASPA)-based chemotherapy have a dismal prognosis. To better define the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT), we conducted a retrospective analysis of data shared with the European Society for Blood and Marrow Transplantation (EBMT) and cooperating Asian centers.
Open in Who Shared Issue with article?

Internet Search Trends Relevant to Interventional Oncology: a Google Trends study (2004-2020)

|
By Philipp Berning, Majid Maybody, Amy R. Deipolyi, Stephen Solomon
| Journal of Interventional Radiology (JVIR) Verified
Article Info Publication History Accepted: July 10, 2021 Received in revised form: June 16, 2021 Received: February 17, 2021 Publication stage In Press Accepted Manuscript Footnotes Conflict of interest and financial disclosures SBS reports grants from Johnson & Johnson, grants from GE Healthcare, grants from Elesta, grants from AngioDynamics, personal fees from Aperture Medical, personal fees from XACT Robotics, personal fees from Varian, personal fees from Microbot, personal fees from...
Open in Who Shared Issue with article?

Understanding myocardial infarction trends during the early COVID‐19 pandemic: an infodemiology study

|
By Omar Dzaye, Garth Graham, Matthias Duebgen, Philipp Berning
| Wiley Online Library Verified
Brief Communication Omar Dzaye, Corresponding Author odzaye@jhmi.edu orcid.org/0000-0001-9483-3510 Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Russell H.
Open in Who Shared Issue with article?
Show More